Literature DB >> 32915263

Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial.

Koen De Winne1, Laure Sorber2, Suzan Lambin3, Vasiliki Siozopoulou3,2, Gabriela Beniuga4, Franceska Dedeurwaerdere5, Nicky D'Haene6, Lionel Habran7, Louis Libbrecht8, Jacques Van Huysse9, Birgit Weynand10, Katrin Wouters11, Patrick Pauwels3,2,12, Karen Zwaenepoel3,2.   

Abstract

A Belgian ring trial for pan-TRK immunohistochemistry (IHC) staining was organised to harmonise pan-TRK IHC staining protocols and interpretation. As a reference method, the VENTANA pan-TRK Assay (clone EPR17341) on the Benchmark Ultra platform was selected. Six samples were selected: 2 negative, 2 fusion positive and 2 samples with wild-type endogenous TRK expression. Each participating laboratory stained the slides using their routine pan-TRK IHC and reported their results. In addition, they were asked to return one TRK-stained slide from each case. The coordinating lab evaluated these slides, compared them with the reference method and scored them. Two clones were used during the ring trial: A7H6R (Cell Signaling) and EPR17341 (Abcam/Ventana). Seven protocols achieved a sufficient performance mark, and three labs were advised to further optimise the protocol. Interpretation of pan-TRK IHC proved to be challenging in cases with physiological TRK expression. In addition, depending on the NTRK fusion partner, the staining can vary strongly in both intensity and staining pattern. Labs using the Ventana ready-to-use system based on the EPR17341 clone and using the recommended protocol settings scored best. However, given some small optimisation, all labs scored well on the technical staining and the succeeding evaluation.

Entities:  

Keywords:  Cancer screening; Immunohistochemistry; NTRK fusions; Ring trial; TRK inhibitor

Mesh:

Substances:

Year:  2020        PMID: 32915263      PMCID: PMC7969564          DOI: 10.1007/s00428-020-02921-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  27 in total

1.  Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

Authors:  Jaclyn F Hechtman; Ryma Benayed; David M Hyman; Alexander Drilon; Ahmet Zehir; Denise Frosina; Maria E Arcila; Snjezana Dogan; David S Klimstra; Marc Ladanyi; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

2.  Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.

Authors:  Diana Bell; Renata Ferrarotto; Li Liang; Ryan P Goepfert; Jie Li; Jing Ning; Russell Broaddus; Randal S Weber; Adel K El-Naggar
Journal:  Virchows Arch       Date:  2019-08-19       Impact factor: 4.064

3.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.

Authors:  S R Knezevich; D E McFadden; W Tao; J F Lim; P H Sorensen
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

5.  ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Authors:  C Marchiò; M Scaltriti; M Ladanyi; A J Iafrate; F Bibeau; M Dietel; J F Hechtman; T Troiani; F López-Rios; J-Y Douillard; F Andrè; J S Reis-Filho
Journal:  Ann Oncol       Date:  2019-09-01       Impact factor: 32.976

6.  An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Authors:  Robert C Doebele; Lara E Davis; Aria Vaishnavi; Anh T Le; Adriana Estrada-Bernal; Stephen Keysar; Antonio Jimeno; Marileila Varella-Garcia; Dara L Aisner; Yali Li; Philip J Stephens; Deborah Morosini; Brian B Tuch; Michele Fernandes; Nisha Nanda; Jennifer A Low
Journal:  Cancer Discov       Date:  2015-07-27       Impact factor: 39.397

7.  Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.

Authors:  Tsutomu Tatematsu; Hidefumi Sasaki; Shigeki Shimizu; Katsuhiro Okuda; Masayuki Shitara; Yu Hikosaka; Satoru Moriyama; Motoki Yano; Jeffrey Brown; Yoshitaka Fujii
Journal:  Mol Clin Oncol       Date:  2014-06-19

Review 8.  Identifying patients with NTRK fusion cancer.

Authors:  J P Solomon; R Benayed; J F Hechtman; M Ladanyi
Journal:  Ann Oncol       Date:  2019-12-24       Impact factor: 32.976

9.  Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing.

Authors:  Danielle A Murphy; Heather A Ely; Robert Shoemaker; Aaron Boomer; Brady P Culver; Ian Hoskins; Josh D Haimes; Ryan D Walters; Diane Fernandez; Joshua A Stahl; Jeeyun Lee; Kyoung-Mee Kim; Jennifer Lamoureux; Jason Christiansen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-08

Review 10.  NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.

Authors:  Alessandro Gambella; Rebecca Senetta; Giammarco Collemi; Stefano Gabriele Vallero; Matteo Monticelli; Fabio Cofano; Pietro Zeppa; Diego Garbossa; Alessia Pellerino; Roberta Rudà; Riccardo Soffietti; Franca Fagioli; Mauro Papotti; Paola Cassoni; Luca Bertero
Journal:  Int J Mol Sci       Date:  2020-01-23       Impact factor: 5.923

View more
  4 in total

1.  NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects.

Authors:  Vasiliki Siozopoulou; Elly Marcq; Koen De Winne; Koen Norga; Gertjan Schmitz; Valerie Duwel; Philippe Delvenne; Evelien Smits; Patrick Pauwels
Journal:  Pathol Oncol Res       Date:  2022-05-11       Impact factor: 2.874

2.  Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.

Authors:  Kiat Hon Tony Lim; Hwai Loong Kong; Kenneth Tou En Chang; Daniel Shao Weng Tan; Iain Bee Huat Tan; Farid Mohamad; Shui Yen Soh; Brendan Nghee-Kheem Pang; Ross Andrew Soo; Su Pin Choo; Wen-Son Hsieh; LeLe Aung
Journal:  Asia Pac J Clin Oncol       Date:  2021-11-21       Impact factor: 1.926

3.  Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.

Authors:  Ronald Carter; Harriet Feilotter; Timothy Feltis; Joshua D Silvertown; Connie Lisle; Laura Semenuk; Colleen Knapp; Jillann Jaynes; Doreen Berg; Nabodita Kaul; Josianne Lachapelle; Leslie Richardson; Marsha Speevak; Haya Sarras; David M Berman
Journal:  Mol Diagn Ther       Date:  2022-10-04       Impact factor: 4.476

Review 4.  NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects.

Authors:  Vasiliki Siozopoulou; Evelien Smits; Koen De Winne; Elly Marcq; Patrick Pauwels
Journal:  Diagnostics (Basel)       Date:  2021-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.